Publications

Allegakoen DV, Sahu PK, Kwong K, Morales J, Bivona TG, Sabnis AJ. The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression. Scientific Reports. 2026. PMID: 42156896

Jhaveri K, Rugo HS, Cortés J, Oliveira M, Howell SJ, Dalenc F, Gomez HL, Hu X, Krivorotko P, Loibl S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Zhukova L, Nardone A, Wadsworth I, D'Cruz C, Wantenaar T, Das D, de Bruin EC, Turner NC. Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42154572

Rosenberg JE, O'Donnell PH, Petrylak DP, Flaig TW, Hoimes CJ, Gupta S, Mar N, Friedlander TW, Tagawa ST, Bilen MA, Brown JR, McKay RR, Merchan JR, Srinivas S, Gorla S, Moreno BH, Davis G, Wirtz HS, Zhu Y, Milowsky MI. EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. ESMO open. 2026. PMID: 42155320

Ginex PK, Thoele K, Ma Q, Searles Vitko A, Gathirua-Mwangi WG, Liepa AM, Panjic EH, Chou E, Ellis HJ, de Courcy J, Clewes C, Taraba J, Rugo HS. Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey. Clinical journal of oncology nursing. 2026. PMID: 42227802

Sweis RF, Long GV, Daud A, Stemmer SM, Jimeno A, Perets R, Kummar S, Patel MR, Khattak A, Abadier M, Van L, Guo R, Do KT, Sullivan RJ. Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42149124

Kodali PB, Vijayaraghavan M. Receipt of healthcare provider advice to quit tobacco use among Indian men. PloS one. 2026. PMID: 42149875

Blumenberg V, Diorio C, Gauthier J, Agrusa JE, Dreyzin A, Hänel G, Espinoza-Gutarra MR, Geer M, Perales MA, Ramakrishna S, Jain MD, Gill S, Locke FL, Shouval R, Subklewe M, Komanduri KV, Chapuis AG, Paczesny S, Rejeski K, Shah NN. Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells. Transplantation and cellular therapy. 2026. PMID: 42144191

Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming M, Klauss G, Lin D, Liu C, Apolo AB, Powles T. TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. Future oncology (London, England). 2026. PMID: 42142358

Vater M, Salgado R, Blige E, Lefebvre H, Strahan A, Gatti-Mays M, Rugo H, Ballman K, Watson M, Wen Y, Leon-Ferre R, Niazi K, Symmans WF, Carey L, AbdulJabbar K, Li Z, Stover DG. QuTILs: Open-Source Image-Based Infiltrating Immune Cell Detection for Research Application. Research square. 2026. PMID: 42183372

Oluwole OO, Crofford L, Jallouk AP, Lee DW, Gardner R, Piquet AL, Jackson SW, Velarde AM, Meyer E, Knight TE, Seshadri MR, Mirza S, Wacker K, Wilfong E. Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and cellular therapy. 2026. PMID: 42134594

Xu X, Mailhot O, Correy GJ, Huang XP, Braz J, Shi D, Srinivasan K, Zielinski K, Holota Y, Kuziv Y, Tsoutsouvas C, Levinzon N, Doruk YU, Rachman M, Diolaiti M, Stevens M, Liu F, Holland K, Hübner H, Wang J, Wu Y, Ashworth A, Makriyannis A, Zhang Y, Moroz Y, Gmeiner P, Abel R, Manglik A, Basbaum AI, Roth BL, Fraser JS, Shoichet BK. Toward a Random Background for Ligand Optimization. bioRxiv : the preprint server for biology. 2026. PMID: 42182464

Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell reports. 2026. PMID: 42118658

Huang F, Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne B, Hsu S, Choi J, Pham J, Chen YA, Weinstein H, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll P, Hong J, Heaphy C, Cooperberg M, Greenland N, Campbell J. Defining the combinatorial nature of gene modules in prostate cancer underlying lineage plasticity and metastasis. Research square. 2026. PMID: 42183352

Aggarwal R, Zhang J, Monk P, Zhu X, Jones R, Linch M, Costin D, de Bono J, Karsh LI, Petrylak DP, Zhang L, Deshpande R, Borderies P, Huang J, O'Neill V, Donkor M, Tagawa S. Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. Journal for immunotherapy of cancer. 2026. PMID: 42114950

Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Ha PK, Algazi AP, Wai KC. Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer. Head & neck. 2026. PMID: 42108213

Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). Future oncology (London, England). 2026. PMID: 42108643

Zeng J, Cheng Z, Chen H, Thompson J, Crosby KT, Han H, Ngo W, Xia C, Rosas-Rivera D, Kang MH, Mao Y, Lee G, Diffley JFX, Song Y, Qiu L, Krah NM, Murthy N, Jackson RN, Liu Y, Ashworth A, Doudna JA. Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding. bioRxiv : the preprint server for biology. 2026. PMID: 42146678

Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu P, Thill M, Curigliano G, Rugo HS. Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer. The oncologist. 2026. PMID: 42095602

Lord CJ, Tutt ANJ, Ashworth A. Two decades of PARP inhibitor synthetic lethality in cancer. Nature. 2026. PMID: 42092061

Rajeeve S, Wilkes M, Zahradka N, Tomalin L, Quidwai M, Pan D, Calafat NJ, Cusack M, Aleman A, Serebryakova K, Kappes K, Jackson H, Agte S, Thibaud S, Sanchez L, Richard S, Richter J, Rodriguez C, Cho HJ, Chari A, Jagannath S, Laganà A, Rossi AC, Parekh S. Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. JCI insight. 2026. PMID: 42084945